Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Other: Prostate Biopsy, Focal Brachytherapy , Assessment of QOL

First Posted Date: 2011-05-17

Last Posted Date: 2018-10-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT01354951

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
North Shore LIJ, New Hyde Park, New York, United States
🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States

Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib

First Posted Date: 2011-05-11

Last Posted Date: 2017-04-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 44

Registration Number: NCT01351623

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Biological: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant

First Posted Date: 2011-05-06

Last Posted Date: 2016-01-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 21

Registration Number: NCT01349647

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

Phase 3

Completed

Conditions: Rectal Cancer

Interventions: Drug: Placebo
Drug: Rifaximin

First Posted Date: 2011-04-29

Last Posted Date: 2024-05-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 69

Registration Number: NCT01345175

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States

Telemedicine Evaluation for Stem Cell Transplant Patients

Not Applicable

Completed

Conditions: Stem Cell Transplant Patients

Interventions: Behavioral: virtual medical visit

First Posted Date: 2011-03-29

Last Posted Date: 2020-08-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 43

Registration Number: NCT01324427

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States

and more 1 locations

Trial of Individual Psychosocial Interventions for Cancer Patients

Completed

Conditions: Advanced Solid Tumor Diseases

Interventions: Behavioral: standard Individual Supportive Psychotherapy (ISP)
Behavioral: Individual Meaning-Centered Psychotherapy (IMCP)
Behavioral: enhanced usual care (EUC)

First Posted Date: 2011-03-25

Last Posted Date: 2024-07-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 346

Registration Number: NCT01323309

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Ipilimumab, Melphalan and Dactinomycin

First Posted Date: 2011-03-25

Last Posted Date: 2018-05-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 26

Registration Number: NCT01323517

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Randomization to No Panitumumab
Drug: panitumumab

First Posted Date: 2011-03-11

Last Posted Date: 2024-07-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 75

Registration Number: NCT01312857

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

and more 5 locations

Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus

Completed

Conditions: Lung Cancer

Interventions: Genetic: obtain tissue specimens

First Posted Date: 2011-02-21

Last Posted Date: 2021-01-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT01300429

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI

Withdrawn

Conditions: Breast Cancer

Interventions: Other: MRI

First Posted Date: 2011-02-16

Last Posted Date: 2012-11-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT01297231

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy